Impella for Cardiogenic Shock: High Expectations From Ongoing Studies

Within the last 24 months, I have had financial relationship(s) with the ineligible company or companies listed below:

• Consultant Fee/Honoraria/Speaker's Bureau - Heartflow; Abiomed; Elucid Bio; Valfix; Therox; Ablative Solutions; Miracor Medical SA; Ancora; Vectorious; Robocath; Neovasc; Cardiomech; Pulnovo; Infraredx; Corflow; Apollo Therapeutics; Occlutech; Impulse Dynamics; Amgen; Medtronic; Abbott Vascular; Millenial Biopharma; Adona Med
• Equity/Stock(s)/Options - SpectraWave; Orchestra Biomed; Applied Therapeutics; Biostar Family of Funds; Aria; Cardiac Success; Valfix; Ancora; Cagent; Xenter
• Grant Support/Research Contract - V-Wave; Cardiovascular Systems Inc; Phillips; Biosense Webster; Abbott; Bioventrix; Vascular Dynamics; Shockwave; Abiomed